Archives
|
Entry
|
Blogger
|
Date
|
Location
|
|
The Icos Alumni Guide, Trubion CEO Resigns, OVP Leads $30M Fate Deal, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
11/19/09 |
Seattle
|
|
Aileron’s New Class of Drugs Shown to Get Inside Cells to Block Prime Cancer Target
|
Luke Timmerman |
11/11/09 |
Boston
|
|
Amylin Forms Global Alliance in Obesity Drug Development; TEDMED’s Show Will Go On, Sequenom Sued for Civil Fraud, & More San Diego Biotech News
|
Bruce V. Bigelow |
11/05/09 |
San Diego
|
|
Amylin, Lilly’s Byetta Wins FDA Approval as Standalone Therapy, Without Combo Drugs
|
Luke Timmerman |
10/30/09 |
San Diego
|
|
Lilly, With New Focus on Innovation (But Not Necessarily Inclusiveness), Opens San Diego Center for Biotech R&D
|
Bruce V. Bigelow |
10/30/09 |
San Diego
|
|
Sequel Pharmaceuticals’ CEO on How to Start a Biotech and Sell it For a Bundle, and Repeat
|
Luke Timmerman |
10/28/09 |
San Diego
|
|
Diabetes drug from San Diego’s Amylin caught up in Aussie Brouhaha
|
Denise Gellene |
10/27/09 |
San Diego
|
|
Faster, Cheaper Stem Cells: Fate Therapeutics Co-Founder, With Scripps Team, Finds Key
|
Luke Timmerman |
10/18/09 |
National
|
|
Flexion Therapeutics Gets $33M For Faster, Cheaper Drug Development
|
Luke Timmerman |
10/16/09 |
Boston
|
|
Dendreon Recruits Aces to Board, Amgen Seeks to Raise Hit Rate, Lee Hood Startup Gets $30M, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
10/15/09 |
Seattle
|
|
Dendreon Recruits Genentech CEO, Former Lilly Manufacturing Chief to Board
|
Luke Timmerman |
10/09/09 |
Seattle
|
|
Merrimack Pharma Grabs $60M Upfront From Sanofi for Cancer Antibody
|
Luke Timmerman |
10/01/09 |
Boston
|
|
Amylin CEO, Putting Boardroom Coup Behind Him, Turns Up Heat on New Diabetes Drug
|
Luke Timmerman |
09/29/09 |
San Diego
|
|
Swine Flu Could Benefit Some Biomedical Companies, Local Biotechs Are Looking Healthier, Arena Happy With Obesity Drug Results, & More San Diego Life Sciences News
|
Bruce V. Bigelow |
09/24/09 |
San Diego
|
|
Five Big Questions For Dendreon’s Analyst Day
|
Luke Timmerman |
09/24/09 |
Seattle
|
|
Ambrx Strikes Deal With Wyeth (Soon-to-be Pfizer) to Make Antibody Drugs
|
Luke Timmerman |
09/18/09 |
San Diego
|
|
$14M for Novomer, $7.3M for Innocentive, $6M for Zendesk, & More Boston-Area Deals News
|
Rebecca Zacks |
08/21/09 |
Boston
|
|
San Diego Biotech Startups Raise New Cash to Treat Anemia, Heart Disease and More
|
Bruce V. Bigelow |
08/19/09 |
San Diego
|
|
Innocentive Raises $7M—One More Time—to Keep Building Problem-Solving Network
|
Wade Roush |
08/17/09 |
Boston
|
|
Aveo Pieces Together a Plan to Rival Big Boys of Cancer Drug World
|
Luke Timmerman |
06/29/09 |
Boston
|
|
UW Stem Cell Startup is Born, Global Health’s “Davos” Arrives, MDRNA Unloads Debt, & More Seattle-Area Life Sciences News
|
Luke Timmerman |
06/18/09 |
Seattle
|
|
Seattle’s Pacific Health Summit, the “Davos” of Global Health, Zeroes in on Tuberculosis
|
Luke Timmerman |
06/16/09 |
Seattle
|
|
Novartis Backing Enlight Biosciences
|
Ryan McBride |
06/15/09 |
Boston
|
|
Aileron Piles on $40M, GenArts Lights Up Lucasfilm’s Screens, Taris Takes on $15M, & More Boston-Area Deals News
|
Rebecca Zacks |
06/12/09 |
Boston
|
|
Aileron Snags $40M From Quartet of Pharma Giants to Develop New Class of Drugs
|
Luke Timmerman |
06/08/09 |
Boston
|
|
Amylin’s Would-Be Savior, Once-Weekly Diabetes Shot, Shows Two-Year Benefit
|
Luke Timmerman |
06/07/09 |
San Diego
|
|
Presage, Fred Hutch Spinoff, Aims to Show Docs Which Cancer Drugs Work, and Which Won’t
|
Luke Timmerman |
05/19/09 |
Seattle
|
|
Icahn Wants to Fix Amylin First, Not Sell on the Cheap, Alex Denner Says
|
Luke Timmerman |
05/19/09 |
San Diego
|
|
Amylin Dissidents Ought to Win Proxy Fight, Influential Advisory Firm Says
|
Luke Timmerman |
05/15/09 |
San Diego
|
|
Icahn Throws Down the Gauntlet, Attacks Biogen Idec’s “Failed Leadership”
|
Luke Timmerman |
05/11/09 |
Boston
|
|
Page 1 of
3 |
next page » |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, and beyond.
© 2007-2009, Xconomy, Inc.
XCONOMY is a registered service mark of Xconomy, Inc.
All rights reserved.
Site designed by
Matthew Bouchard, produced by
Andrew Koyfman,
and powered by WordPress.
